Join
Live feed
·
INSIDERFilingvia Quantisnow
Travere Therapeutics Inc. logo

Director Coughlin Timothy sold $141,342 worth of shares (3,250 units at $43.49) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 52,250 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
TVTX· Travere Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track TVTX (Travere Therapeutics Inc.) and more on Quantisnow.